

Abstract

The present invention relates to a novel member of the tumor necrosis factor
5 family of receptors. In particular, isolated nucleic acid molecules are provided encoding
the human TR9 receptor. TR9 polypeptides are also provided as are vectors, host cells
and recombinant methods for producing the same. The invention further relates to
screening methods for identifying agonists and antagonists of TR9 receptor activity.

2025 RELEASE UNDER E.O. 14176